Karen Adler-Storthz

Karen Adler-Storthz

Auto-generated profile, based on publicly available information

Karen Adler-Storthz

The Univ. of Texas Health Science Ctr. at Houston (United States)

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003
Verified
Journal Article
Closed access
KDKristina R Dahlstrom
Kristina R Dahlstrom
KAKaren Adler-Storthz
Karen Adler-Storthz
CECarol J Etzel
Carol J Etzel
ZLZhensheng Liu
Zhensheng Liu
LDLaura Dillon
Laura Dillon
ESErich M Sturgis
Erich M Sturgis

1 January 2009 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
AVAnne L. van de Ven
Anne L. van de Ven
KAKaren Adler-Storthz
Karen Adler-Storthz
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
The identification of unique molecular markers of cancer and its precursors has stimulated the development of new cancer-screening tools. A technology facilitating the noninvasive identification of precancerous lesions at high risk for progression would have important clinical benefits. Molecular-specific optical contrast agents have garnered attention for their ability to selectively label cells expressing markers of interest. Optical probes targeting extracellular biomarkers have advanced to preclinical animal models and pilot clinical trials.1, 2, 3, 4, 5, 6, 7, 8 The development of contrast agents targeted to intracellular biomarkers has proved to be more challenging. Multifunctional contrast agents designed to utilize cell uptake mechanisms have been reported;9, 10, 11, 12 however, the engineering of highly specific, optical probes with the appropriate physiochemical properties for cell internalization is difficult and not always feasible. There is need for a strategy to facilitate the intracellular delivery of existing contrast agents into live cells.

9 September 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SCScott B. Cantor
Scott B. Cantor
JYJose-Miguel Yamal
Jose-Miguel Yamal
Martial GuillaudMartial Guillaud
Martial Guillaud
DCDennis D. Cox
Dennis D. Cox
EAE. Neely Atkinson
E. Neely Atkinson
MFMichele Follen
Michele Follen
Testing emerging technologies involves the evaluation of biologic plausibility, technical efficacy, clinical effectiveness, patient satisfaction, and cost‐effectiveness. The objective of this study was to select an effective classification algorithm for optical spectroscopy as an adjunct to colposcopy and obtain preliminary estimates of its accuracy for the detection of CIN 2 or worse. We recruited 1,000 patients from screening and prevention clinics and 850 patients from colposcopy clinics at two comprehensive cancer centers and a community hospital. Optical spectroscopy was performed, and 4,864 biopsies were obtained from the sites measured, including abnormal and normal colposcopic areas. The gold standard was the histologic report of biopsies, read 2 to 3 times by histopathologists blinded to the cytologic, histopathologic, and spectroscopic results. We calculated sensitivities, specificities, receiver operating characteristic (ROC) curves, and areas under the ROC curves. We identified a cutpoint for an algorithm based on optical spectroscopy that yielded an estimated sensitivity of 1.00 [95% confidence interval (CI) = 0.92–1.00] and an estimated specificity of 0.71 [95% CI = 0.62–0.79] in a combined screening and diagnostic population. The positive and negative predictive values were 0.58 and 1.00, respectively. The area under the ROC curve was 0.85 (95% CI = 0.81–0.89). The per‐patient and per‐site performance were similar in the diagnostic and poorer in the screening settings. Like colposcopy, the device performs best in a diagnostic population. Alternative statistical approaches demonstrate that the analysis is robust and that spectroscopy works as well as or slightly better than colposcopy for the detection of CIN 2 to cancer.

2 April 2007 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
MSMichael Scheurer
Michael Scheurer
LDLaura M Dillon
Laura M Dillon
GCGeorgia Chen
Georgia Chen
MFMichele Follen
Michele Follen
KAKaren Adler-Storthz
Karen Adler-Storthz
Background: Few reports of the utilization of an accurate, cost-effective means for measuring HPV oncogene transcripts have been published. Several papers have reported the use of relative quantitation or more expensive Taqman methods. Here, we report a method of absolute quantitative real-time PCR utilizing SYBR-green fluorescence for the measurement of HPV E7 expression in cervical cytobrush specimens. Results: The construction of a standard curve based on the serial dilution of an E7-containing plasmid was the key for being able to accurately compare measurements between cervical samples. The assay was highly reproducible with an overall coefficient of variation of 10.4%. Conclusion: The use of highly reproducible and accurate SYBR-based real-time polymerase chain reaction (PCR) assays instead of performing Taqman-type assays allows low-cost, high-throughput analysis of viral mRNA expression. The development of such assays will help in refining the current screening programs for HPV-related carcinomas.

14 August 2007 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
MSMichael Scheurer
Michael Scheurer
Martial GuillaudMartial Guillaud
Martial Guillaud
GTGuillermo Tortolero‐Luna
Guillermo Tortolero‐Luna
CMCalum McAulay
Calum McAulay
MFMichele Follen
Michele Follen
KAKaren Adler‐Storthz
Karen Adler‐Storthz
Background: Image cytometry has provided two highly sensitive markers for the identification of the malignant potential of squamous lesions. Aneuploidy and chromatin texture have been investigated as quantitative measures of nuclear damage in premalignant lesions and carcinoma. Real‐time PCR methods have evolved to yield highly specific measurements of mRNA expression in very sparse cellular samples.Methods: Human papillomavirus (HPV) 16 and 18 E7 mRNA expression was measured using quantitative RT‐PCR. DNA index and chromatin measures were taken from image cytology samples. The chromatin features, through discriminant analysis, were aggregated into a score, and both measurements were related to mRNA expression.Results: mRNA level and DNA index show an increasing trend over increasing histological grades. However, DNA index and chromatin score were not correlated to mRNA levels in these samples. Chromatin score differed by mRNA type found with HPV 18 infected samples having a higher score than those with HPV 16. Samples infected with HPV 16 and HPV 18 had even higher chromatin scores.Conclusions: DNA index and chromatin score were not directly correlated with mRNA levels. However both mRNA and DNA index were related to histological grade, and chromatin score was associated with HPV type. Therefore, DNA index and mRNA levels could be independent predictors of cervical dysplasia, and chromatin score could be related to the viral integration process in cells infected with HPV 18 or dual infections. © 2007 Clinical Cytometry Society

1 January 2009 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
AVAnne L. van de Ven
Anne L. van de Ven
KAKaren Adler-Storthz
Karen Adler-Storthz
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
Advances in molecular-specific optical contrast agents have recently shown promise for the detection of cancer and its precursors. Targeting agents that have been successfully used for optical detection of cancer biomarkers in preclinical models include antibodies,1, 2, 3, 4, 5, 6 growth factors,7, 8, 9, 10, 11 peptide analogs of extracellular ligands,12, 13, 14, 15 and enzymatically activatable polymers.16, 17, 18, 19, 20 The coupling of optical tags to these targeting agents allows molecular events to be monitored noninvasively in vivo.21 These molecular-specific optical contrast agents have the potential to provide dynamic, real-time information without the need for biopsy and associated patient discomfort.